Mantle Cell Lymphoma · line 3 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | aggressive |
| Linked regimen | None |
| ID | IND-MCL-3L-LISOCEL |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-01 | pending_clinical_signoff |
| Diseases | DIS-MCL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 3L+ option for r/r MCL post-cBTKi per TRANSCEND NHL-001 MCL cohort. Trial source SRC-TRANSCEND-NHL-001-ABRAMSON-2020 in KB but covers DLBCL primary publication; MCL-cohort publication SRC-TRANSCEND-MCL-WANG-2024 absent from KB at chunk authoring time — citing NCCN-BCELL-2025 + ESMO-MCL-2024 pending source-stub creation (flagged for trial-source ingest follow-up). Missing entity flag: dedicated REG- entity for MCL liso-cel not authored (recommended_regimen empty); lymphodepletion + dose mirrors DLBCL REGIMEN-LISOCEL-DLBCL-3L until MCL-specific regimen authored — flagged for REG follow-up. Brexucel (IND-MCL-3L-BREXUCEL-CART) is alternative; product selection driven by safety profile preference.
Used By
No reverse references found in the YAML corpus.